| Article ID | Journal | Published Year | Pages | File Type | 
|---|---|---|---|---|
| 5700752 | European Journal of Surgical Oncology (EJSO) | 2017 | 7 Pages | 
Abstract
												Ablation or resection for liver-limited recurrence after surgery for colorectal liver metastases is associated with improved overall survival compared with systemic chemotherapy alone, and should always be considered for patients with resectable liver recurrence. Although ablation seemed to be associated with a shorter progression-free survival, post-procedure morbidity was significantly lower. The choice between ablation and resection should therefore be made on a personalised basis.
											Related Topics
												
													Health Sciences
													Medicine and Dentistry
													Oncology
												
											Authors
												Aurélien Dupré, Robert P. Jones, Rafael Diaz-Nieto, Stephen W. Fenwick, Graeme J. Poston, Hassan Z. Malik, 
											